'LEGO-Like' building blocks to halt cell growth wins Hebrew University prize

June 07, 2006

A method for delivery of drugs to targeted cells through the design of specific molecular structures called SIB (Small Integrated Building Blocks) has won a prestigious scientific prize for a Ph.D. student in organic chemistry at the Hebrew University of Jerusalem

Jerusalemite Nir Qvit, 34, will be one of those receiving the Kaye Innovation Award on June 13, during the 69th meeting of the Hebrew university Board of Governors.

Qvit has shown through his research that it is possible to greatly increase drug delivery efficiency by designing specific molecular structures made up of known pharmaceutically effective peptides (small protein molecules) that are attached to tailor-made, geometric-like structures called "scaffolding."

Each scaffold is specifically designed to combine the peptides in such a way that they will form an effective medicinal combination and so that they will bind to the receptors of specific targeted cells. Qvit refers to his process as somewhat analogous to building different kinds of structures through the use of LEGO.

Qvit, a student of Prof. Chaim Gilon of the Department of Organic Chemistry, has shown, for example, that with a particular combination of peptides and scaffold design, it is possible to create a synthetic molecule that will bind to the IGF-1 (insulin-like growth factor-1) receptor. IGF-1 is a protein that plays a critical role in the proliferation of many cancers, including prostate, lung, breast, colon and brain cancers. The binding action of the molecule to the receptor inhibits the activation of the IGF-1 protein in the cells, thus halting the cancerous growth.

Through this process of "combinational chemistry," involving peptides and scaffold design, Qvit says that many different types of molecules can be built that will reach specifically targeted cells, offering hope for treatment of not only cancer, but other diseases as well, without harming healthy cells.
-end-
The Kaye Innovation Awards have been given annually since 1994. Isaac Kaye of England, a prominent industrialist in the pharmaceutical industry, established the awards to encourage faculty, staff, and students of the Hebrew University to develop innovative methods and inventions with good commercial potential which will benefit the university and society.

The Hebrew University of Jerusalem

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.